METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS
In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.
1 . A method for inhibiting the growth and/or proliferation of a my c-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor.
2 . The method of claim 1 , wherein the myc-driven tumor cell is of neural origin.
3 . The method of claim 2 , wherein the myc-driven tumor cell of neural origin is derived from a primary neuroblastoma tumor, a metastatic neuroblastoma tumor or a brain tumor.
4 . The method of claim 1 , wherein the myc-driven tumor cell is an ovarian cancer cell.
5 . The method of claim 1 , wherein the myc-driven tumor cell is selected from the group consisting of rhabdomyosarcoma, liver cancer, melanoma, breast cancer, colon cancer, prostate cancer, Burkitt's lymphoma and lung cancer.
6 . The method of claim 1 , wherein the tumor cell is contacted in vitro.
7 . The method of claim 1 , wherein the tumor cell is contacted in vivo in a mammalian subject.
8 . The method of claim 1 , wherein the CSNK1ε inhibitor is a small molecule inhibitor.
9 . The method of claim 8 , wherein the CSNK1ε inhibitor is selected from the group consisting of IC261, PF-4800567, and PF-670462.
10 . A method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.
11 . The method of claim 10 , wherein the subject is suffering from a tumor comprising myc-driven tumor cells of neural origin.
12 . The method of claim 11 , wherein the myc-driven tumor cell of neural origin is derived from a primary neuroblastoma tumor, a metastatic neuroblastoma tumor or a brain tumor.
13 . The method of claim 10 , wherein the myc-driven tumor cell is ovarian cancer.
14 . The method of claim 10 , wherein the myc-driven tumor cell is selected from the group consisting of rhabdomyosarcoma, liver cancer, melanoma, breast cancer, colon cancer, prostate cancer, Burkitt's lymphoma and lung cancer.
15 . The method of claim 10 , wherein the subject is further provided one or more additional anti-cancer therapies.
16 . The method of claim 15 , wherein the additional anti-cancer therapy comprises chemotherapy.
17 . The method of claim 16 , wherein the myc-driven tumor cell is resistant to cisplatin and the CSNK1ε inhibitor renders the cell susceptible to cisplatin.
18 . The method of claim 10 , wherein the CSNK1ε inhibitor is a small molecule inhibitor.
19 . The method of claim 18 , wherein the CSNK1ε inhibitor is selected from the group consisting of IC261, PF-4800567, and PF-670462.
20 . The method of claim 10 , further comprising the step of determining whether the tumor in said subject comprises myc-driven tumor cells prior to treatment with said composition comprising a CSNK1ε inhibitor.